The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Phase I INSIGHT platform trial: eftilagimod alpha with avelumab in advanced solid tumors
Thorsten O. Goetze, MD, University Cancer Center Frankfurt, Frankfurt, Germany, discusses results from stratum D of the INSIGHT platform trial (NCT03252938), a Phase I study evaluating feasibility and safety of subcutaneous eftilagimod alpha, a soluble LAG-3 protein, in combination with avelumab in patients with advanced solid tumors. Combined treatment with avelumab and eftilagimod alpha seems feasible and safe, in addition, no unexpected adverse events occurred. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
